Health TrialsbyHealthPanel

Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)

ConditionsST Elevation Myocardial InfarctionNon-ST Elevation Myocardial InfarctionLDL-cholesterol
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJena University Hospital

About this trial

Intensive Lipid-Lowering Therapy guided by a cloud-based Software System (CLIMEDO GmbH) improves (European Society of Cardiolofgy/European Atherosclerosis Society) ESC/EAS-guideline recommended LDL-cholesterol target attainment and adherence in patients with ST-Elevation Myocardial (STEMI) and Non-ST-Elevation Myocardial Infarctions (NSTEMI).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients with ST- and Non-ST-elevation myocardial infarctions

Disqualifiers

patient without informed concent

patients in cardiogenic shock

patients with contraindication to lipid-lowering therapy

patients on lipid-lowering medications on admission

Trial design

Design model

Parallel

Treatments tested in this trial

  • statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran

    Drug

    dietary advice for low cholesterol food

Treatment groups

300 Participants
are divided into 2 treatment groups
Group A: Cloud-based softwareActive comparator 1 intervention
Group B: Standard CarePlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

LDL-C

LDL-C target attainment (ESC/EAS dyslipidemia guidelines)

Time frame
6 months

Secondary outcomes

1

side-effects of lipid lowering therapy

muscle pain, hair loss, dizziness, joint pain, depression

Time frame
6 months
2

adherence to LLT

regular LLT

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jena University Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: